Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPR720 in Mycobacterium Avium Complex (MAC) Pulmonary Disease
NCT04553406Phase 2Terminated
- Sponsor
- Spero Therapeutics
- Start
- Dec 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fobrepodacin in mycobacterium avium complex pulmonary disease (MAC-PD), sponsored by Spero Therapeutics. Started Dec 2020; status: terminated.
02
Drugs
fobrepodacin
03
Conditions
mycobacterium avium complex pulmonary disease (MAC-PD)
Beyond the preview
Go deeper on NCT04553406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04553406.